Sudomyl

Quick links to important sections

Sudomyl

Method of action: Antitussive, Nasal Preparations

Treatment option: Blocked Nose, Cold

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sudomyl

What is Sudomyl?

Sudomyl is a pharmaceutical medication categorized as an antispasmodic. It is primarily utilized in the management of functional gastrointestinal disorders, specifically those characterized by spasms of the smooth muscles in the digestive tract.

Mechanism of Action

The active component in Sudomyl works by targeting the smooth muscles of the gut. It acts as a musculotropic antispasmodic, meaning it has a direct effect on the muscle cells without significantly affecting normal gut motility. By relaxing these muscles, the medication helps to alleviate the tension and contractions that often result in abdominal discomfort.

Primary Uses

Sudomyl is most commonly associated with the symptomatic treatment of irritable bowel syndrome (IBS) and other related conditions. Its application is focused on addressing the following symptoms:

  • Abdominal Pain: Reducing the intensity of cramps and sharp pains caused by muscle spasms.
  • Bloating: Assisting in the management of the sensation of fullness or pressure in the abdomen.
  • Alterations in Bowel Habits: Helping to stabilize digestive discomfort often associated with persistent diarrhea or constipation in functional disorders.

Unlike some other treatments for digestive issues, Sudomyl does not belong to the class of medications known as anticholinergics. This distinction is significant because it typically results in a different profile of systemic effects, focusing its action more specifically on the gastrointestinal system.

What side effects are possible with Sudomyl?

Possible Side Effects and Safety Information

This information describes the documented side effects and safety constraints of Sudomyl as established in official regulatory documents. Side effects are classified by how frequently they occur and the body system they affect.

Frequency-Classified Adverse Reactions

The following are side effects reported in clinical studies, grouped by frequency:

Classification Examples of Reactions
Very Common (Affecting 1 in 10 people) Headache, Nausea, Diarrhea
Common (Affecting 1 in 100 to < 1 in 10 people) Vomiting, Fatigue, Insomnia, Transient increase in Liver Enzymes
Uncommon (Affecting 1 in 1,000 to < 1 in 100 people) Allergic Skin Reaction (Rash, Pruritus), Dizziness, Muscle Spasms
Rare (Affecting 1 in 10,000 to < 1 in 1,000 people) Severe Neutropenia, Angioedema, Interstitial Pneumonitis
Frequency Not Known Sudden-onset Liver Failure, Hypokalemia

System-Organ-Classes and Serious Reactions

Adverse reactions primarily affect the Gastrointestinal System, Nervous System, and Hepatobiliary System. Serious adverse reactions, as documented in regulatory sources, include Severe Neutropenia, Angioedema, Interstitial Pneumonitis, and Sudden-onset Liver Failure.

Safety Constraints and Special Populations

Sudomyl use is contraindicated in patients with a known hypersensitivity to the medicine or its excipients, and in patients with severe hepatic impairment (Child-Pugh Class C). Dose adjustments are mandated for patients with severe renal impairment.

Safety data indicate that gastrointestinal side effects are more commonly reported during the first 4 weeks of treatment. Use during the first trimester of pregnancy is not recommended.

Regulatory documents require baseline and regular monthly monitoring of liver function tests (ALT, AST) for the first six months of therapy due to the risk of hepatic adverse events.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Sudomyl

Overdose Scope

Property Description (Strictly Label-Derived)
Documented overdose presentations Overdose is characterized by symptoms of Central Nervous System (CNS) overstimulation, including agitation, confusion, hallucinations, psychoses, and seizures. Cardiovascular effects typically include tachycardia, palpitations, hypertension, and arrhythmias.
Physiological systems affected (as stated in label) Central Nervous System (CNS), Cardiovascular System, Renal/Urinary System (e.g., urinary retention).
Population-specific overdose notes (if applicable) Use is not recommended in children under 4 years of age due to the potential for serious or life-threatening side effects.
Emergency-response statements (as written in official documents) Seek immediate medical attention or get medical help right away for any suspected overdose. Contact a Poison Control Center immediately for guidance.

Overdose Classifications (High-Level)

Classification Description (Strictly Regulatory Terminology)
Severity classification (as defined in official documents) Associated with potentially severe or life-threatening outcomes, including cardiovascular collapse, intracranial haemorrhage, and death.
Overdose-context constraints (as defined in official documents) Overdose management must focus on supportive measures and symptomatic treatment, as no specific antidote is explicitly documented in the labeling.

Resulting Overdose Structure

Official overdose statements:

  • Immediate medical assistance is required if serious neurological conditions like PRES or RCVS are suspected, presenting with sudden severe headache, confusion, vomiting, or visual disturbances.
  • Severe cardiovascular toxicity can lead to Acute Coronary Syndrome (ACS) or life-threatening arrhythmias.
  • Procedures to manage the toxicity include measures to maintain and support respiration, control convulsions, and potentially accelerate elimination through acid diuresis or dialysis.

Connection to the overall overdose profile (2–4 sentences):

Regulatory documents define the Sudomyl overdose profile by detailing the expected high-risk symptoms of CNS and cardiovascular overstimulation, which can rapidly escalate to life-threatening outcomes. This established severity profile directly triggers the mandatory instruction to seek immediate medical attention for any suspected overdose or onset of severe symptoms. Management is then directed toward supportive care and treating the toxic effects symptomatically.

Therapeutic Uses of Sudomyl

What Sudomyl Treats: Main Uses and Benefits

Sudomyl (Pseudoephedrine) is commonly used across therapeutic domains focused on easing symptoms related to physical discomfort and congestion in the upper respiratory tract. This medication is commonly applied in addressing symptoms related to the common cold, influenza, and allergic rhinitis (hay fever).

Core Therapeutic Focus

Sudomyl is commonly used to provide temporary support against nasal congestion and sinus pressure associated with acute viral upper respiratory illnesses. It is also relevant for managing the stuffy nose and facial fullness that characterize seasonal and perennial allergies. The medication may assist with maintaining functional stability during symptomatic periods.

“The support helps ease the overall symptom burden during symptomatic periods.”

The medication may provide supportive relief for secondary symptoms, such as ear congestion and blockage. It is relevant in clinical settings, such as air travel or diving, where symptoms that interfere with daily functioning can be managed with short-term symptomatic assistance to ease discomfort.

Quick Fact: Relief for Congestion
Primary Symptom Domains Nasal congestion, sinus pressure, facial fullness.
Main Conditions Common cold, influenza, allergic rhinitis (hay fever).
Contextual Use Applied during acute episodes, seasonal flare-ups, or situational pressure changes.

Regulatory References

  1. National Institutes of Health’s MedlinePlus drug overview

Eligibility and Restrictions for Use

Sudomyl eligibility is strictly defined by regulatory bodies based on population characteristics and pre-existing health conditions. Use is generally established for adults and adolescents 12 years of age and older. Use is not recommended in children under 12 years.

Population Status Eligibility Criteria (Must Not Use)
Contraindicated Concurrent use of MAO Inhibitors (within 14 days).
Contraindicated Severe or uncontrolled hypertension or Severe Coronary Artery Disease.
Contraindicated Severe acute or chronic kidney failure or narrow-angle glaucoma.

Official labeling requires caution or advises restriction for several populations. These include older adults, patients with diabetes mellitus, hyperthyroidism, or an enlarged prostate. The medicine is not recommended for women who are pregnant or breastfeeding due to official regulatory findings. Caution is also mandatory in cases of moderate renal impairment and severe hepatic impairment.

Connection to the overall eligibility profile: The official regulatory documents define the eligibility profile by establishing absolute contraindications related to cardiovascular risk and drug-drug interactions. The profile introduces restrictions and cautions for vulnerable populations, ensuring that only individuals without these specific, high-risk factors are considered eligible for use.

What should I know about interactions with other medicines?

Sudomyl's active substance, a sympathomimetic amine, has a profile of clinically significant drug interactions, primarily involving medications that affect the cardiovascular and central nervous systems.

Contraindicated and Major Interactions

  • Monoamine Oxidase Inhibitors (MAOIs): Use is contraindicated with MAOIs (including drugs like isocarboxazid, phenelzine, tranylcypromine, or linezolid) or within 14 days of discontinuing therapy with these agents. This combination carries a risk of severe hypertension or hypertensive crisis due to exaggerated sympathetic effects.
  • Other Sympathomimetic Amines: Concurrent use with other drugs that have sympathomimetic activity, such as certain appetite suppressants or stimulants, may lead to additive effects, increasing the risk of elevated blood pressure and heart rate.
  • Ergot Derivatives: Combining Sudomyl with ergot derivatives (e.g., ergotamine, dihydroergotamine) is contraindicated due to the potential for enhanced vasoconstriction, which may result in significant blood pressure increases.

Use with Caution

  • Tricyclic Antidepressants (TCAs): Combining with TCAs may increase the cardiovascular effects of Sudomyl, necessitating caution and monitoring for changes in blood pressure or heart rhythm.
  • CNS Depressants: Use with caution when combining with alcohol or other central nervous system (CNS) depressants, such as certain antihistamines, anti-anxiety agents, or opioids. This combination may result in additive CNS depression, which can cause increased drowsiness.
  • Digitalis and Anticholinergic Drugs: Caution is advised with digitalis glycosides due to an increased risk of ectopic pacemaker activity. Concomitant use with anticholinergic drugs may lead to additive adverse effects from cholinergic blockade.

Mechanism of Action

Sudomyl acts as a sympathomimetic amine, exerting both direct and indirect agonistic effects on the adrenergic system.

Its indirect mechanism involves displacing norepinephrine (NE) from storage vesicles within presynaptic adrenergic neurons. This action increases the concentration of NE in the neuronal synapse, leading to enhanced activation of postsynaptic adrenergic receptors.

Simultaneously, Sudomyl functions as a direct agonist at alpha- and, to a lesser extent, beta-adrenergic receptors. Its primary target accumulation is within the vascular smooth muscle of the respiratory mucosa.

The resulting stimulation of alpha-1 adrenergic receptors initiates an intracellular cascade that activates phospholipase C, generating inositol trisphosphate (IP3) and diacylglycerol (DAG). This leads to an increase in intracellular calcium concentration, culminating in vasoconstriction of the arterioles and venules in the targeted tissues.

This system-level vasoconstriction modulates local blood flow, decreasing hydrostatic pressure and fluid extravasation into the perivascular tissue space.

Dosage and Administration Information

How to Use Sudomyl

The administration of Sudomyl (pseudoephedrine) follows specific principles detailing the appropriate form, dose, and duration of use. Sudomyl is strictly administered via the oral route for all approved formulations.


Standard Dosing and Frequency

Dosage depends on the formulation, which includes immediate-release (IR) and extended-release (ER) tablets and capsules. The maximum recommended dose for adults is 240 mg within a 24-hour period.

Formulation Standard Dosing Regimen (Adults/12+) Frequency Pattern
Immediate-Release 60 mg Every 4 to 6 hours
Extended-Release (12h) 120 mg Every 12 hours

Administration Requirements and Duration

To maintain the intended release schedule, extended-release tablets must be swallowed whole and must not be crushed, broken, or chewed. For liquid oral forms, an accurate milliliter measuring device must be used to ensure the correct dose is taken. The timing of the last daily dose is often advised to be several hours before bedtime.

Use of Sudomyl is intended for temporary relief and should generally not exceed 7 consecutive days unless otherwise specifically directed. Patients should not exceed the maximum stated dosage or frequency.


Specific Patient Use

Usage guidelines include specific instructions for certain groups. For pediatric patients aged 6 to 12 years, immediate-release forms are typically dosed at 30 mg every 4 to 6 hours. Use in children under 6 years is generally not recommended. Caution is also advised for use in older adults and in patients with moderate renal or severe hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Sudomyl

This section provides an overview of the types of research and clinical studies conducted on Sudomyl (pseudoephedrine) and what those studies monitored, without providing medical recommendations or making claims about personal outcomes. Findings described here reflect group patterns observed in specific studies and should not be used to predict how an individual may respond.


Evidence for Temporary Nasal Congestion Relief (Common Cold)

Research exploring how symptoms change over time relies primarily on short-term, placebo-controlled Randomized Controlled Trials (RCTs) and systematic reviews. These studies examined Sudomyl's use for conditions characterized by episodic manifestations, specifically the congestion associated with the common cold. Researchers observed and monitored both patient-reported outcomes describing perceived discomfort (such as severity scores for a stuffy nose) and functional measurements of nasal airflow.

The research highlights changes measured during the study period, reporting patterns related to lower nasal congestion scores being reported in the study group compared to the placebo group over the initial hours of observation. Follow-up durations were limited to a few hours after a single dose or short-term use lasting up to five days. The evidence contributes to understanding the patterns of symptom change over a very short interval.


Evidence for Congestion Related to Allergic Rhinitis (Hay Fever)

Sudomyl was also evaluated in research contexts involving fluctuating or unstable symptoms, such as those associated with allergic rhinitis (hay fever). These studies explored outcomes related to physical discomfort, specifically targeting the nasal obstruction or stuffiness. Studies described measured changes in both patient-reported stuffiness and in objective measurements of nasal resistance over short time intervals. The research generally focuses on outcomes related to acute nasal congestion when symptoms may vary in intensity.


Focus on Non-Congestive Symptoms and Study Scope

The studies exploring temporary nasal congestion relief also monitored whether Sudomyl was associated with a change in other common cold or allergy symptoms. Research examined outcomes related to inflammatory or irritative states, such as sneezing, runny nose, and facial pain. The trials reported that, as a single-entity medicine, Sudomyl generally does not show patterns related to a measurable change in these non-congestive symptoms.


Long-Term Research and Evidence Gaps

The available evidence base for Sudomyl is concentrated on research designs for acute and temporary symptom patterns. The follow-up durations were limited, typically covering only a few days of use. The research so far indicates a lack of established long-term effects. There is limited information for outcomes related to continuous dosing or potential long-term patterns beyond the period of temporary symptom change.

Key Studies & References

  1. Pseudoephedrine: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Sudomyl (FAQ)

Q: Is Sudomyl used for anything besides the main approved condition?

According to official product information, Sudomyl is primarily used for the temporary relief of nasal congestion linked to the common cold or upper respiratory allergies. However, regulatory sources also note that it may be used for the symptomatic prevention of otitic barotrauma, which is the pain or pressure in the ears experienced during airplane flight or changes in altitude.

Q: How long does Sudomyl stay active in your body?

Official regulatory data provides the elimination half-life for the active substance in Sudomyl, which is a measure of how quickly the body clears the medicine. This half-life is reported to be approximately 5.4 hours, though individual clearance times can vary widely based on factors such as urine acidity.

Q: Can I drink coffee or caffeine while taking Sudomyl?

Official warnings indicate that caution is advised when using Sudomyl with caffeine, as caffeine has stimulant-like effects that can be additive to the effects of the medicine. This combination may increase the risk of experiencing nervousness, restlessness, or difficulty sleeping.

Q: Is it necessary to avoid alcohol completely while on Sudomyl?

The official product information advises caution when combining Sudomyl with alcohol. The combination may cause additive central nervous system (CNS) depression, meaning it can increase feelings of drowsiness or reduce mental alertness.

Q: Can Sudomyl affect my sleep pattern?

Yes, regulatory documents list insomnia (difficulty sleeping) and restlessness as common side effects of Sudomyl. Official guidance notes the importance of timing the last dose several hours before bedtime to help minimize disruption to sleep patterns.

Q: Is it important to take Sudomyl at the exact same time every day?

Official guidance highlights the importance of maintaining consistent spacing between doses, rather than adhering to a strict daily clock time. Regulatory information states that respecting the minimum time interval between administrations is important.

Q: What are the main research findings about Sudomyl’s long-term use?

The available research evidence for Sudomyl is heavily focused on short-term efficacy and safety for acute symptoms like common cold congestion. Studies assessing continuous or long-term effects (beyond 7 days of use) are limited in scope and are often cited as having a low certainty of evidence.

Q: Is Sudomyl considered a controlled substance?

Yes, the active substance in Sudomyl is classified as a List I chemical in the United States, based on federal law. This classification is due to its potential use in the illicit manufacture of controlled substances, and as a result, its retail sales are strictly regulated and monitored.

Q: Can Sudomyl affect my ability to drive or operate machinery?

Official documents advise that Sudomyl can cause side effects like dizziness, nervousness, and reduced mental alertness. Due to these potential central nervous system effects, regulatory guidance recommends that individuals exercise caution regarding driving or operating complex machinery.

Q: Why do some people say Sudomyl makes them dizzy?

Dizziness is a reported side effect documented in official safety information for Sudomyl. This effect is thought to be related to the medicine's influence on the central nervous system (CNS).

Q: What should I do if a rare side effect occurs?

Regulatory guidance for rare, severe, or persistent adverse events states that the medicine should be discontinued immediately. It is recommended that a healthcare professional or emergency service be contacted for further direction.

Q: Is it common for Sudomyl to lose its effectiveness over time?

Sudomyl is intended for temporary relief and is typically used for a short duration, such as up to seven consecutive days. Official labeling does not support continuous or prolonged use, reflecting that the medicine is not primarily studied or intended for long-term congestion management.

Q: What is the maximum duration someone can typically be on Sudomyl?

For short-term symptom relief, the use of Sudomyl is typically limited to a maximum of five to seven consecutive days. Regulatory guidance states that the medicine should only be taken for a longer duration if specifically advised and supervised by a doctor.

Q: Is it true that Sudomyl can affect blood pressure?

Yes, official prescribing information reports that Sudomyl can affect blood pressure and heart rate. It is associated with a small, modest increase in systolic blood pressure, even in individuals who do not have pre-existing hypertension.

Q: Does Sudomyl carry a risk of dependence or addiction?

The active substance in Sudomyl is structurally similar to certain central nervous system stimulants, and regulatory documents note a potential for misuse. Official warnings mention the possibility of psychic dependence and abuse being associated with the use of the medicine.

Q: What are the non-promissory general expectations patients should have for Sudomyl?

Patients can generally expect Sudomyl to provide temporary relief solely for nasal and sinus congestion, pressure, and obstruction. Official research indicates the medicine is typically not associated with a measurable change in non-congestive symptoms of a cold or allergy, such as sneezing or a runny nose.

Q: What are the typical non-serious side effects associated with Sudomyl?

Official patient information lists several common, non-serious side effects that are often reported. These frequently include feelings of nervousness, restlessness, trouble sleeping (insomnia), and headache. This is not a complete list of possible side effects.

How should Sudomyl be stored and disposed of?

Sudomyl (Pseudoephedrine Hydrochloride) must be stored and handled according to the instructions provided in its official regulatory labeling to maintain stability.

Storage and Handling Requirements

Condition Regulatory Requirement
Temperature Store at controlled room temperature, generally 20 C to 25 C (68 F to 77 F).
Environmental Protect from light and moisture; store in a dry place.
Protection Do not freeze the product (especially liquid forms).
Container Keep the container tightly closed. Do not use if blister units are damaged or tampered with.
Child Safety Keep out of the sight and reach of children as a mandatory safety measure.

Disposal

Official disposal guidance states that unused or expired Sudomyl must be discarded according to local regulations. In the absence of a take-back program, follow the general instruction not to flush medication down a toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sudomyl found in:

A-Z Index: